Biosciences Area

  • About Biosciences
    • Leadership
    • Area Operations Centers
    • Strategic Plan and Reports
    • Strategic Programs Development Group
    • Contact Information
  • Our Science
    • Area Programs
    • Strategic Initiatives
    • Biological Systems and Engineering
    • Environmental Genomics and Systems Biology
    • Molecular Biophysics and Integrated Bioimaging
    • DOE Joint Genome Institute
  • Media and Events
    • News
    • Announcements
    • Behind the Breakthroughs
    • Events Calendar
    • Seminar Series
  • Staff Resources
    • Commonly Used Acronyms
    • Communications
    • Hiring and Recruitment
    • Hybrid & Telework Resources
    • IDEA
    • Intellectual Property, Industry Engagement, and Entrepreneurship
    • LDRD Information
    • Logos and Templates
    • Mentoring Program
  • Search

Biosciences Participates at East Bay STEM Career Awareness Day

April 27, 2017

Biosciences Area researchers and staff participated at the annual East Bay STEM Career Awareness Day on April 27, 2017, at Wareham Development’s Aquatic Park Center in West Berkeley, home to Biosciences Operations @ Berkeley and several Area research groups.

The event was led by Cal State University East Bay’s Institute for STEM Education in partnership with local businesses and organizations, and was aimed at providing insight into potential STEM careers and educational opportunities in the region. Three hundred high school students from Berkeley, Emeryville, Oakland and Richmond engaged in activities around this year’s theme:, “What problem(s) are you trying to solve?” Students had the opportunity to network with a variety of STEM professionals during tours, a working lunch and exhibitor tabling.

Potential Targeted Therapy Found Against Triple-negative Breast Tumors

October 25, 2016

A triple-negative breast cancer cell (MDA-MB-231) in metaphase during cell division. (Image courtesy the National Cancer Institute)

Paul Yaswen of the Environmental Genomics & Systems Biology Division was part of a team of researchers from Berkeley Lab, UCSF, and the Buck Institute who co-authored an October 24 Nature Medicine publication on their research that showed the potential of PIM1 kinase inhibition for treatment of patients with triple-negative breast cancer (TNBC). TNBC, which lacks the expression of the estrogen, progesterone, and HER2 receptors, represents the breast cancer subtype with the poorest outcome. No targeted therapy is available against this subtype due to lack of validated molecular targets.

Berkeley Lab Scientists to Develop Better Way to Screen Chemicals for Cancer-Causing Effects

June 24, 2015

The vast majority of the thousands of chemicals in our homes and workplaces have not been tested to determine if they cause cancer due to limitations in current testing methods. Berkeley Lab scientists are developing a cell culture that better identifies chemicals that increase breast cancer susceptibility.

Was this page useful?

Send
like not like

About Biosciences

  • Leadership
  • Area Operations Centers
  • Inclusion, Diversity, Equity, and Accountability (IDEA)
  • Contact

Divisions & User Facility

  • Biological Systems and Engineering
  • Environmental Genomics and Systems Biology
  • Molecular Biophysics and Integrated Bioimaging
  • DOE Joint Genome Institute

Resources

  • A-Z Index
  • Phonebook
  • Logos
  • Acronyms
  • Integrated Safety Management
Questions & Comments
Follow us: Mastodon LinkedIn YouTube